A phase I trial of dactinomycin intraven
โ
Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones;
๐
Article
๐
1985
๐
John Wiley and Sons
๐
English
โ 204 KB
๐ 3 views
Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered